{
  "url": "https://openlegislation.uk/eu-decision-2006-540/annex-I",
  "json_url": "https://openlegislation.uk/eu-decision-2006-540/annex-I.json",
  "legislation": "eudn/2006/540",
  "legislation_title": "Commission Decision of 11 April 2006 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2006 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council (notified under document number C(2006) 1483) (Only the Danish, Dutch, English, Estonian, Finnish, French, German, Italian, Slovenian, Spanish and Swedish texts are authentic) (Text with EEA relevance) (2006/540/EC)",
  "legislation_url": "https://openlegislation.uk/eu-decision-2006-540",
  "path": "annex/I",
  "kind": "annex",
  "number": "I",
  "heading": null,
  "text": "Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following countries have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as ‘essential’ under the Protocol when combined with following active ingredients:\nTable 1\nSource: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp\nCountry\nShort-acting Beta Agonist Bronchodilators\nSalbutamol\nTerbutaline\nFenoterol\nOrciprenaline\nReproterol\nCarbuterol\nHexoprenaline\nPirbuterol\nClenbuterol\nBitolterol\nProcaterol\nAustria\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nBelgium\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nCyprus\nX\nCzech Republic\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nDenmark\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nEstonia\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nFinland\nX\nFrance\nX\nGermany\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nGreece\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nHungary\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nIreland\nX\nItaly\nX\nLatvia\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nLithuania\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nLuxembourg\nX\nMalta\nX\nNetherlands\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nPoland\nX\nPortugal\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nNorway\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nSlovak Republic\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nSlovenia\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nX\nSpain\nX\nSweden\nX\nUnited Kingdom\nX\nTable 2\nSource: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp\nCountry\nInhaled steroids\nBeclomethasone\nDexamethasone\nFlunisolide\nFluticasone\nBudesonide\nTriamcinolone\nAustria\nBelgium\nX\nX\nX\nX\nX\nX\nCyprus\nCzech Republic\nX\nX\nX\nX\nX\nX\nDenmark\nX\nX\nEstonia\nX\nX\nX\nX\nX\nX\nFinland\nX\nX\nFrance\nX\nX\nGermany\nX\nX\nX\nX\nX\nX\nGreece\nHungary\nX\nX\nX\nX\nX\nX\nIreland\nX\nX\nItaly\nX\nX\nX\nLatvia\nX\nX\nX\nX\nX\nX\nLithuania\nLuxembourg\nMalta\nX\nX\nPoland\nPortugal\nX\nX\nNetherlands\nX\nX\nX\nX\nX\nX\nNorway\nSlovak Republic\nX\nX\nX\nX\nX\nX\nSlovenia\nX\nX\nX\nX\nX\nX\nSpain\nX\nX\nSweden\nX\nX\nX\nX\nX\nUnited Kingdom\nX\nTable 3\nSource: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp\nCountry\nNon-steroidal anti-inflammatories\nCromoglicic acid\nNedrocromil\nAustria\nBelgium\nX\nX\nCyprus\nCzech Republic\nX\nX\nDenmark\nX\nX\nEstonia\nX\nX\nFinland\nX\nX\nFrance\nX\nX\nGermany\nX\nX\nGreece\nX\nX\nHungary\nIreland\nItaly\nLatvia\nX\nX\nLithuania\nLuxembourg\nMalta\nPoland\nPortugal\nX\nNetherlands\nX\nX\nNorway\nSlovak Republic\nX\nX\nSlovenia\nX\nX\nSpain\nX\nSweden\nUnited Kingdom\nTable 4\nSource: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp\nCountry\nAnticholinergic Bronchodilators\nIpratropium bromide\nOxitropium Bromide\nAustria\nBelgium\nX\nX\nCyprus\nX\nX\nCzech Republic\nX\nX\nDenmark\nX\nX\nEstonia\nX\nX\nFinland\nX\nX\nFrance\nGermany\nX\nX\nGreece\nX\nX\nHungary\nX\nX\nIreland\nX\nX\nItaly\nLatvia\nLithuania\nLuxembourg\nMalta\nX\nX\nNetherlands\nX\nX\nPoland\nPortugal\nX\nNorway\nSlovak Republic\nX\nX\nSlovenia\nSpain\nX\nX\nSweden\nX\nX\nUnited Kingdom\nX\nX\nTable 5\nSource: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp\nCountry\nLong-acting Beta Agonist Bronchodilators\nFormoterol\nSalmeterol\nAustria\nBelgium\nCyprus\nCzech Republic\nDenmark\nEstonia\nFinland\nFrance\nGermany\nX\nX\nGreece\nHungary\nIreland\nItaly\nX\nLatvia\nLithuania\nLuxembourg\nMalta\nNetherlands\nPoland\nPortugal\nNorway\nSlovak Republic\nSlovenia\nSpain\nSweden\nUnited Kingdom\nTable 6\nSource: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp\nCountry\nCombinations of active ingredients in a single MDI\nAustria\nBelgium\nCyprus\nCzech Republic\nDenmark\nEstonia\nFinland\nFrance\nGermany\nX\nGreece\nHungary\nIreland\nItaly\nLatvia\nLithuania\nLuxembourg\nMalta\nNetherlands\nPoland\nPortugal\nNorway\nSlovak Republic\nSlovenia\nSpain\nSweden\nUnited Kingdom",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eudn/2006/540/annex/I",
    "retrieved_at": "2026-11-01T15:17:31.910127+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}